XNAS
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-12 | Q3 2025 | — | -0.34 | — | $0 | — | — | — | — |
| 2025-08-14 | Q2 2025 | — | -0.64 | — | $0 | — | -3.79% | +276.52% | +137.88% |
| 2025-03-26 | Q4 2024 |
| — |
| -1.69 |
| — |
| $0 |
| — |
| -5.56% |
| -10.42% |
| -16.67% |
| 2024-11-07 | Q3 2024 | — | -2.45 | — | $0 | — | -2.47% | -8.23% | -4.94% |
| 2024-08-09 | Q2 2024 | — | -2.42 | — | $0 | — | +1.88% | +0.85% | +0.51% |
| 2023-11-08 | Q3 2023 | -22.50 | -41.25 | -83.33% | $0 | ❌ Miss | -8.00% | -5.30% | -87.12% |
| 2023-08-11 | Q2 2023 | -60.00 | -60.00 | +0.00% | $0 | ➖ Inline | — | — | — |
| 2023-05-22 | Q1 2023 | -41.25 | -86.25 | -109.09% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.